A5072229255- SARS-CoV-2 and COVID-19 Research
- Monoclonal and Polyclonal Antibodies Research
- Hepatitis B Virus Studies
- Viral Infections and Outbreaks Research
- COVID-19 Clinical Research Studies
- Bacillus and Francisella bacterial research
- SARS-CoV-2 detection and testing
- Viral Infections and Vectors
- Immunotherapy and Immune Responses
- Viral gastroenteritis research and epidemiology
- Animal Virus Infections Studies
- Cytomegalovirus and herpesvirus research
- CAR-T cell therapy research
- Biochemical and Structural Characterization
- Respiratory viral infections research
- RNA and protein synthesis mechanisms
- Glycosylation and Glycoproteins Research
- T-cell and B-cell Immunology
- Vector-borne infectious diseases
- Plant Virus Research Studies
- COVID-19 Impact on Reproduction
- Yersinia bacterium, plague, ectoparasites research
- Cytokine Signaling Pathways and Interactions
- Blood groups and transfusion
- Congenital Anomalies and Fetal Surgery
Academy of Military Medical Sciences
2016-2025
National Vaccine and Serum Institute
2014-2021
University of Manitoba
2020-2021
Public Health Agency of Canada
2020
Washington University in St. Louis
2002-2012
Developing therapeutics against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) could be guided by the distribution of epitopes, not only on receptor binding domain (RBD) Spike (S) protein but also across full protein. We isolated and characterized monoclonal antibodies (mAbs) from 10 convalescent COVID-19 patients. Three mAbs showed neutralizing activities authentic SARS-CoV-2. One mAb, named 4A8, exhibits high neutralization potency both pseudotyped SARS-CoV-2 does bind RBD....
Abstract The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome 2 (SARS-CoV-2) presents a global public health threat. Most research on therapeutics against SARS-CoV-2 focused the receptor binding domain (RBD) Spike (S) protein, whereas vulnerable epitopes and functional mechanism non-RBD regions are poorly understood. Here we isolated characterized monoclonal antibodies (mAbs) derived from convalescent COVID-19 patients. An mAb targeting N-terminal...
Abstract The SARS-CoV-2 Omicron variant shows substantial resistance to neutralization by infection- and vaccination-induced antibodies, highlighting the demands for research on continuing discovery of broadly neutralizing antibodies (bnAbs). Here, we developed a panel bnAbs against other variants concern (VOCs) elicited vaccination adenovirus-vectored COVID-19 vaccine (Ad5-nCoV). We also investigated human longitudinal antibody responses following demonstrated how evolved over time. A...
Current SARS-CoV-2 Omicron subvariants impose a heavy burden on global health systems by evading immunity from most developed neutralizing antibodies and vaccines. Here, we identified nanobody (aSA3) that strongly cross-reacts with the receptor binding domain (RBD) of both SARS-CoV-1 wild-type (WT) SARS-CoV-2. The dimeric construct aSA3 (aSA3-Fc) tightly binds potently neutralizes WT Based X-ray crystallography, engineered bispecific dimer (2-3-Fc) fusing aSA3-Fc to aRBD-2, previously...
Abstract The pandemic of COVID-19 caused by SARS-CoV-2 continues to spread around the world. Mutant strains are constantly emerging. At present, Omicron variants have become mainstream. In this work, we carried out a systematic and comprehensive analysis reported spike protein antibodies, counting epitopes genotypes these antibodies. We further comprehensively analyzed impact mutations on antibody classified antibodies according their binding patterns. found that H-RBD class were...
Antibodies are key proteins in the immune system that can reversibly and non-covalently bind specifically to their corresponding antigens, forming antigen–antibody complexes. They play a crucial role recognizing foreign or self-antigens during adaptive response. Monoclonal antibodies have emerged as promising class of biological macromolecule therapeutics with broad market prospects. In process antibody drug development, engineering challenge is improve affinity candidate antibodies, without...
Abstract Coronavirus disease 2019 (COVID-19), driven by SARS-CoV-2, is a severe infectious that has become global health threat. Vaccines are among the most effective public tools for combating COVID-19. Immune status critical evaluating safety and response to vaccine, however, evolution of immune during immunization remains poorly understood. Single-cell RNA sequencing (scRNA-seq) represents powerful tool dissecting multicellular behavior discovering therapeutic antibodies. Herein,...
The global spread of SARS-CoV-2 and its variants poses a serious threat to human health worldwide. Recently, the emergence Omicron has presented new challenge prevention control COVID-19 pandemic. A convenient reliable in vitro neutralization assay is an important method for validating efficiency antibodies, vaccines, other potential drugs. Here, we established effective based on pseudovirus carrying full-length spike (S) protein HIV-1 backbone, with luciferase reporter gene inserted into...
Enterovirus 71 (EV71) infection can cause severe disease and lead to death in children. Recurring outbreaks of EV71 have been reported several countries. Interferons (IFNs) used for decades treat types viral infection, but a limited ability inhibit replication. Herein, we intend investigate the mechanisms by which inhibits cellular type I IFN response. In this study, MRC-5 (human embryonic lung fibroblast) or RD rhabdomyosarcoma) cells were infected with EV71, then treated without IFN-α2b....
Tetanus neurotoxin (TeNT) produced by Clostridium tetani is one of the most poisonous protein substances. Neutralizing antibodies against TeNT can effectively prevent and cure toxicosis. Using purified Hc fragments (TeNT-Hc) as an antigen, three specific neutralizing antibody clones recognizing different epitopes were selected from a human immune scFv phage display library. The (2-7G, 2-2D, S-4-7H) inhibit binding between TeNT-Hc differentiated PC-12 cells in vitro. Moreover, 2-7G inhibited...
Abstract The Hendra and Nipah viruses (HNVs) are highly pathogenic pathogens without approved interventions for human use. In addition, the interaction pattern between attachment (G) fusion (F) glycoproteins required virus entry remains unclear. Here, we isolate a panel of Macaca-derived G-specific antibodies that cross-neutralize HNVs via multiple mechanisms. most potent antibody, 1E5, confers adequate protection against challenge in female hamsters. Crystallography demonstrates 1E5 has...
Ebola virus (EBOV) can cause severe hemorrhagic fever in humans, and no approved treatment is currently available. Although several antibodies have achieved good protection animal models, the potential emerging isolates of ebolavirus unknown effects experimental humans underscore need to develop additional address threat Ebola. Here, we isolated a series memory B cell-derived monoclonal from healthy Chinese adults vaccinated with Ad5-EBOV. These were encoded by diverse germline genes had...
ABSTRACT The anthrax protective antigen (PA) is the central component of three-part toxin, and it primary immunogenic in approved AVA vaccine “next-generation” recombinant PA (rPA) vaccines. Animal models have indicated that PA-specific antibodies (AB) are sufficient to protect against infection with Bacillus anthracis . In this study, we investigated domain specificity, affinity, mechanisms neutralization, synergistic effects from a single donor following vaccination rPA vaccine....
The Rift Valley fever virus (RVFV) is an arthropod-borne that can not only cause severe disease in domestic animals but also humans. However, the licensed vaccines or available therapeutics for humans do exist. Here, we report two Gn-specific neutralizing antibodies (NAbs), isolated from a rhesus monkey immunized with recombinant human adenoviruses type 4 expressing Gn and Gc protein (rHAdV4-GnGcopt). NAbs were both able to protect host cells RVFV infection. interactions between then...
Yersinia pestis (Y. pestis) has caused an alarming number of deaths throughout recorded human history, and novel prophylactics therapeutics are necessary given its potential as a bioweapon. Only one monoclonal antibody been identified to date that provides complete protection against Y. pestis. Here, we describe second murine (F2H5) provided 141 infection when administered prophylactically Balb/c mice (100 μg intravenously). We humanized F2H5, characterized ability bind the F1 protein...
Lassa virus (LASV) is a rodent-borne arenavirus circulating in West African regions that causes fever (LF). LF normally asymptomatic at the initial infection stage, but can progress to severe disease with multiorgan collapse and hemorrhagic fever. To date, therapeutic choices are limited, there no approved vaccine for avoiding LASV infection. Adenoviral vector-based vaccines represent an effective countermeasure against because of their safety adequate immunogenicity, as demonstrated use...
Coronavirus disease 2019 (COVID-19) has caused over 220,000 deaths so far and is still an ongoing global health problem. However, the immunopathological changes of key types immune cells during after virus infection remain unclear. Here, we enriched CD3+ CD19+ lymphocytes from peripheral blood mononuclear COVID-19 patients (severe recovered at early or late stages) healthy people (SARS-CoV-2 negative) revealed transcriptional profiles in these by comprehensive single-cell transcriptome V(D)J...
Clostridium tetani causes life-threatening disease by producing tetanus neurotoxin (TeNT), one of the most toxic protein substances. Toxicosis can be prevented and cured administration anti-TeNT neutralizing antibodies. Here, we identified a series monoclonal antibodies (mAbs) derived from memory B cells healthy adult immunized with C-terminal domain TeNT (TeNT-Hc). Thirteen mAbs bound to both toxoid (TT) TeNT-Hc, while two recognized only TT. VH3-23 was frequently used germline gene in...
SARS-CoV-2, a type of respiratory virus, has exerted great impact on global health and economy over the past three years. Antibody-based therapy was initially successful but later failed due to accumulation mutations in spike protein virus. Strategies that enable antibodies resist virus escape are therefore significance. Here, we engineer bispecific SARS-CoV-2 neutralizing nanobody secretory Immunoglobulin A (SIgA) format, named S2-3-IgA2m2, which shows broad potent neutralization against...